241 related articles for article (PubMed ID: 26778149)
21. Molecular hybridization conceded exceptionally potent quinolinyl-oxadiazole hybrids through phenyl linked thiosemicarbazide antileishmanial scaffolds: In silico validation and SAR studies.
Taha M; Ismail NH; Ali M; Rashid U; Imran S; Uddin N; Khan KM
Bioorg Chem; 2017 Apr; 71():192-200. PubMed ID: 28228228
[TBL] [Abstract][Full Text] [Related]
22. Structure based medicinal chemistry-driven strategy to design substituted dihydropyrimidines as potential antileishmanial agents.
Rashid U; Sultana R; Shaheen N; Hassan SF; Yaqoob F; Ahmad MJ; Iftikhar F; Sultana N; Asghar S; Yasinzai M; Ansari FL; Qureshi NA
Eur J Med Chem; 2016 Jun; 115():230-44. PubMed ID: 27017551
[TBL] [Abstract][Full Text] [Related]
23. Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach.
Pandey RK; Sharma D; Bhatt TK; Sundar S; Prajapati VK
J Biomol Struct Dyn; 2015; 33(12):2541-53. PubMed ID: 26305585
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of Thiocarbohydrazones and Evaluation of their in vitro Antileishmanial Activity.
Muhammad MT; Ghouri N; Khan KM; Arshia ; Choudhary MI; Perveen S
Med Chem; 2018; 14(7):725-732. PubMed ID: 29332596
[TBL] [Abstract][Full Text] [Related]
25. Targeting malaria and leishmaniasis: Synthesis and pharmacological evaluation of novel pyrazole-1,3,4-oxadiazole hybrids. Part II.
Verma G; Khan MF; Mohan Nainwal L; Ishaq M; Akhter M; Bakht A; Anwer T; Afrin F; Islamuddin M; Husain I; Alam MM; Shaquiquzzaman M
Bioorg Chem; 2019 Aug; 89():102986. PubMed ID: 31146198
[TBL] [Abstract][Full Text] [Related]
26. Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against Leishmania donovani trypanothione reductase.
Pandey RK; Kumbhar BV; Sundar S; Kunwar A; Prajapati VK
J Recept Signal Transduct Res; 2017 Feb; 37(1):60-70. PubMed ID: 27147242
[TBL] [Abstract][Full Text] [Related]
27. New antiprotozoal agents: Synthesis and biological evaluation of different 4-(7-chloroquinolin-4-yl) piperazin-1-yl)pyrrolidin-2-yl)methanone derivatives.
Ansari MF; Hayat F; Inam A; Kathrada F; van Zyl RL; Coetzee M; Ahmad K; Shin D; Azam A
Bioorg Med Chem Lett; 2017 Feb; 27(3):460-465. PubMed ID: 28027871
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of novel derivatives of 4-methylbenzimidazole and evaluation of their biological activities.
Taha M; Ismail NH; Jamil W; Rashwan H; Kashif SM; Sain AA; Adenan MI; Anouar el H; Ali M; Rahim F; Khan KM
Eur J Med Chem; 2014 Sep; 84():731-8. PubMed ID: 25069019
[TBL] [Abstract][Full Text] [Related]
29. Benzo[b]thiophene-thiazoles as potent anti-Toxoplasma gondii agents: Design, synthesis, tyrosinase/tyrosine hydroxylase inhibitors, molecular docking study, and antioxidant activity.
Rosada B; Bekier A; Cytarska J; Płaziński W; Zavyalova O; Sikora A; Dzitko K; Łączkowski KZ
Eur J Med Chem; 2019 Dec; 184():111765. PubMed ID: 31629163
[TBL] [Abstract][Full Text] [Related]
30. Novel Heteroaryl Selenocyanates and Diselenides as Potent Antileishmanial Agents.
Baquedano Y; Alcolea V; Toro MÁ; Gutiérrez KJ; Nguewa P; Font M; Moreno E; Espuelas S; Jiménez-Ruiz A; Palop JA; Plano D; Sanmartín C
Antimicrob Agents Chemother; 2016 Jun; 60(6):3802-12. PubMed ID: 27067328
[TBL] [Abstract][Full Text] [Related]
31. Metal-based compounds as prospective antileishmanial agents: inhibition of trypanothione reductase by selected gold complexes.
Colotti G; Ilari A; Fiorillo A; Baiocco P; Cinellu MA; Maiore L; Scaletti F; Gabbiani C; Messori L
ChemMedChem; 2013 Oct; 8(10):1634-7. PubMed ID: 24039168
[TBL] [Abstract][Full Text] [Related]
32. Identification of Kaurane-Type Diterpenes as Inhibitors of Leishmania Pteridine Reductase I.
Herrera-Acevedo C; Flores-Gaspar A; Scotti L; Mendonça-Junior FJB; Scotti MT; Coy-Barrera E
Molecules; 2021 May; 26(11):. PubMed ID: 34063939
[TBL] [Abstract][Full Text] [Related]
33. Discovery of new 1,4-disubstituted 1,2,3-triazoles:
Şahin İ; Çeşme M; Yüce N; Tümer F
J Biomol Struct Dyn; 2023 Mar; 41(5):1988-2001. PubMed ID: 35057704
[TBL] [Abstract][Full Text] [Related]
34. Antileishmanial phytochemical phenolics: molecular docking to potential protein targets.
Ogungbe IV; Erwin WR; Setzer WN
J Mol Graph Model; 2014 Mar; 48():105-17. PubMed ID: 24463105
[TBL] [Abstract][Full Text] [Related]
35. Carboxylate derivatives of tributyltin (IV) complexes as anticancer and antileishmanial agents.
Waseem D; Butt AF; Haq IU; Bhatti MH; Khan GM
Daru; 2017 Apr; 25(1):8. PubMed ID: 28376844
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, in vitro and in silico studies of novel potent urease inhibitors: N-[4-({5-[(3-Un/substituted-anilino-3-oxopropyl)sulfanyl]-1,3,4-oxadiazol-2-yl}methyl)-1,3-thiazol-2-yl]benzamides.
Abbasi MA; Hassan M; Aziz-Ur-Rehman ; Siddiqui SZ; Raza H; Shah SAA; Seo SY
Bioorg Med Chem; 2018 Jul; 26(13):3791-3804. PubMed ID: 29903414
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, modeling and biological evaluation of hybrids from pyrazolo[1,5c]pyrimidine as antileishmanial agents.
Atta KFM; Ibrahim TM; Farahat OOM; Al-Shargabi TQ; Marei MG; Bekhit AA; El Ashry ESH
Future Med Chem; 2017 Oct; 9(16):1913-1929. PubMed ID: 29028366
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy of leishmaniasis part XIII: design and synthesis of novel heteroretinoid-bisbenzylidine ketone hybrids as antileishmanial agents.
Tiwari A; Kumar S; Shivahare R; Kant P; Gupta S; Suryawanshi SN
Bioorg Med Chem Lett; 2015 Jan; 25(2):410-3. PubMed ID: 25475205
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, in vitro - In vivo biological evaluation of novel thiazolopyrimidine compounds as antileishmanial agent with PTR1 inhibition.
Istanbullu H; Bayraktar G; Karakaya G; Akbaba H; Perk NE; Cavus I; Podlipnik C; Yereli K; Ozbilgin A; Debelec Butuner B; Alptuzun V
Eur J Med Chem; 2023 Feb; 247():115049. PubMed ID: 36577215
[TBL] [Abstract][Full Text] [Related]
40. Novel 3-aryl-5-substituted-coumarin analogues: Synthesis and bioactivity profile.
Kavetsou E; Katopodi A; Argyri L; Chainoglou E; Pontiki E; Hadjipavlou-Litina D; Chroni A; Detsi A
Drug Dev Res; 2020 Jun; 81(4):456-469. PubMed ID: 31943295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
